Tarsus is developing its lead candidate tp 03, potentially the first fda approved therapy for demodex blepharitis, and a pipeline of investigational therapies targeting eye care, dermatology, and. Xdemvy (lotilaner ophthalmic solution) 0.25% is fda approved in the united states for the treatment of demodex blepharitis. tarsus is also developing tp 03 for the treatment of meibomian gland disease, which is currently being studied in a phase 2a clinical trial.
“tp 03 is the first and only investigational therapy to meet all endpoints in demodex blepharitis pivotal trials. this nda submission is a significant milestone for tarsus and most importantly, it provides hope to millions of demodex blepharitis patients who have been living with this damaging disease,” said bobby azamian, m.d., ph.d. Tarsus pharmaceuticals inc. announced that the fda approved lotilaner ophthalmic solution 0.25% (xdemvy) for the treatment of demodex blepharitis. lotilaner ophthalmic solution 0.25%, formerly known as tp 03, is the first and only fda approved treatment to directly target demodex mites, the root cause of demodex blepharitis. Xdemvy (lotilaner ophthalmic solution) 0.25%, formerly known as tp 03, is a novel prescription eye drop designed to treat demodex blepharitis by targeting and eradicating the root cause of the. Tp 03 is now also being studied for the treatment of meibomian gland disease in patients with demodex mites. tarsus pharmaceuticals inc. today announced that it has submitted a new drug application (nda) to the fda for tp 03 (lotilaner ophthalmic solution, 0.25%) for the treatment of demodex blepharitis.
Comments are closed.